Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions has proceeded uninterrupted by the pandemic and has been completed on time. The second phase of manufacturing the nanoparticle material is expected to continue on schedule as the Company makes ready for its first human study.
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
December 7, 2023
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited